FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer.

Auteurs : De Silva P, Garaud S, Solinas C, de Wind A, Van den Eyden G, Jose V, Gu-Trantien C, Migliori E, Boisson A, Naveaux C, Duvillier H, Craciun L, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Année : 2019
Journal : EBioMedicine
Volume : 39
Pages : 226-238

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.

Auteurs : Huober J, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Lang I, Smith I, Boyle F, Xu B, Lecocq C, Wildiers H, Jouannaud C, Hackman J, Dasappa L, Ciruelos E, Toral Pena JC, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber Rd, Piccart-Gebhart M, Di Cosimo S
Année : 2019
Journal : Eur J Cancer
Volume : 118
Pages : 169-177

The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.

Auteurs : Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Peña L, Daidone MG, Huober J, Gori S, Cinieri S, Torri V, Baselga J, Piccart-Gebhart M, De Braud FG, Apolone G, Verderio P, Tagliabue E
Année : 2019
Journal : Eur J Cancer
Volume : 118
Pages : 1-9

Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial.

Auteurs : Holmes EM, Bradbury I, Williams LS, Korde L, de Azambuja E, Fumagalli D, Moreno-Aspitia A, Baselga J, Piccart-Gebhart M, Dueck AC, Gelber Rd
Année : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1507-1513

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation.

Auteurs : Brandão M, Reyal F, Hamy AS, Piccart-Gebhart M
Année : 2019
Journal : ESMO Open
Volume : 4
Pages : e000515

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.

Auteurs : Lambertini M, Campbell C, Gelber Rd, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno-Aspitia A, Piccart-Gebhart M, Loi S, de Azambuja E
Année : 2019
Journal : Breast Cancer Res Treat
Volume : 177
Pages : 103-114

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).

Auteurs : McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, Benelli M, Romagnoli D, Bonechi M, Boccalini G, Pestrin M, Galardi F, De Luca F, Biganzoli L, Piccart-Gebhart M, Gradishar WJ, Chia S, Di Leo A, Malorni L
Année : 2019
Journal : Eur J Cancer
Volume : 114
Pages : 55-66

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Auteurs : Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber Rd, Coates AS, Goldhirsch A, Thürlimann B, Regan MM
Année : 2019
Journal : J Clin Oncol
Volume : 37
Pages : 105-114

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Auteurs : Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E, Ignatiadis M
Année : 2019
Journal : Cancer
Volume : 125
Pages : 307-316

Progress in adjuvant systemic therapy for breast cancer.

Auteurs : Pondé NF, Zardavas D, Piccart-Gebhart M
Année : 2019
Journal : Nat Rev Clin Oncol
Volume : 16
Pages : 27-44

Mammaprint™: a comprehensive review.

Auteurs : Brandão M, Pondé N, Piccart-Gebhart M
Année : 2019
Journal : Future Oncol
Volume : 15
Pages : 207-224

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37.298 women with early breast cancer in 26 randomised trials.

Auteurs : Early Breast Cancer Trialists Collaborative Group, + collaborators (among others :, Philippson C, Larsimont D, Nogaret JM, Piccart-Gebhart M
Année : 2019
Journal : Lancet
Volume : 393
Pages : 1440-1452

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.

Auteurs : Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn HJ, Winer EP, Thurlimann B
Année : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1541-1557

Systemic treatment of patients with early breast cancer: recent updates and state of the art.

Auteurs : Caparica R, Brandão M, Piccart-Gebhart M
Année : 2019
Journal : Breast
Volume : 48 Suppl 1
Pages : S7-S20

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Auteurs : Pondé N, Aftimos P, Piccart-Gebhart M
Année : 2019
Journal : Curr Treat Options Oncol
Volume : 20
Pages : 37

ER+/HER2+ breast cancer: are we really de-escalating?

Auteurs : de Azambuja E, Piccart-Gebhart M
Année : 2019
Journal : Ann Oncol
Volume : 30
Pages : 875-877

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer.

Auteurs : Loi S, Michiels S, Baselga J, Bartlett JMS, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Michael Dixon J, Piccart-Gebhart M, Sotiriou C
Année : 2019
Journal : PLoS One
Volume : 14
Pages : e0216175

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.

Auteurs : Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M
Année : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 3581-3588

Tumor dormancy at bedside: A late awakening.

Auteurs : Demicheli R, Desmedt C, Piccart-Gebhart M, Biganzoli E
Année : 2019
Journal : Breast
Volume : 45
Pages : 61-63

ESR1 mutations in metastatic lobular breast cancer patients.

Auteurs : Desmedt C, Pingitore J, Rothé F, Marchio C, Clatot F, Rouas G, Richard F, Bertucci F, Mariani O, Galant C, Fribbens C, OLeary B, Van den Eynden G, Salgado R, Turner NC, Piccart-Gebhart M, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C
Année : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pages : 9